NASDAQ:ALIM - Alimera Sciences Stock Price, Forecast & News

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Alimera Sciences shares reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

Alimera Sciences Inc (NASDAQ:ALIM) released its quarterly earnings data on Tuesday, October, 29th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.60). The biopharmaceutical company had revenue of $12.85 million for the quarter, compared to the consensus estimate of $12.75 million. View Alimera Sciences' Earnings History.

Alimera Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Alimera Sciences.

Alimera Sciences will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 brokerages have issued 12 month target prices for Alimera Sciences' shares. Their forecasts range from $15.00 to $45.00. On average, they expect Alimera Sciences' share price to reach $30.00 in the next year. This suggests a possible upside of 353.9% from the stock's current price. View Analyst Price Targets for Alimera Sciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alimera Sciences.

Headlines about ALIM stock have been trending very positive recently, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alimera Sciences earned a news sentiment score of 3.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Alimera Sciences.

Alimera Sciences saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 31,900 shares, a decline of 57.0% from the January 15th total of 74,100 shares. Based on an average trading volume of 76,200 shares, the short-interest ratio is presently 0.4 days. Currently, 0.8% of the company's shares are sold short. View Alimera Sciences' Current Options Chain.

Some companies that are related to Alimera Sciences include Cassava Sciences (SAVA), Menlo Therapeutics (MNLO), ProMetic Life Sciences (PFSCF), Xeris Pharmaceuticals (XERS), TapImmune (MRKR), Helix Biopharma (HBPCF), AcelRx Pharmaceuticals (ACRX), Inflarx (IFRX), CymaBay Therapeutics (CBAY), Millendo Therapeutics (MLND), Genprex (GNPX), Clearside Biomedical (CLSD), NeuBase Therapeutics (NBSE), Paratek Pharmaceuticals (PRTK) and CannTrust (CTST).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), Opko Health (OPK), Agenus (AGEN), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), CorMedix (CRMD), Aldeyra Therapeutics (ALDX) and Advanced Micro Devices (AMD).

Alimera Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (4.04%), Renaissance Technologies LLC (1.52%), Royce & Associates LP (0.93%), JW Asset Management LLC (0.55%) and Geode Capital Management LLC (0.21%). Company insiders that own Alimera Sciences stock include James R Largent, John Philip Jones, John Snisarenko and Richard S Eiswirth Jr. View Institutional Ownership Trends for Alimera Sciences.

ALIM stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Renaissance Technologies LLC, Royce & Associates LP, JW Asset Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Alimera Sciences.

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALIM stock can currently be purchased for approximately $6.61.

Alimera Sciences has a market capitalization of $32.85 million and generates $46.97 million in revenue each year. Alimera Sciences employs 124 workers across the globe.View Additional Information About Alimera Sciences.

The official website for Alimera Sciences is http://www.alimerasciences.com/.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]